Omega-3 Fatty Acids
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound class | Omega-3 fatty acids — ALA (18:3), EPA (20:5) and DHA (22:6) |
|---|---|
| CAS | 463-40-1 (ALA) · 10417-94-4 (EPA) · 6217-54-5 (DHA) |
| ALA to EPA conversion | Approximately 5–8% in adults |
| ALA to DHA conversion | Under 0.5%, and lower in men — the key sourcing fact |
| Functional split | EPA: eicosanoid precursor · DHA: structural membrane lipid |
| Critical specification | Peroxide value, anisidine value, TOTOX · contaminant panel for marine |
| Claim strength | High for the conversion arithmetic and EPA/DHA distinction |
| Buy from Herbuno | Omega 3 Fatty Acids Powder · DHA 10% Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: Omega-3 denotes the position of the first double bond counting from the methyl terminus, three carbons in. The class designation groups together fatty acids of very different chain length and function, which is convenient for labelling and misleading for formulation, because the plant and marine members behave differently in essentially every respect that matters.
The three that matter commercially: Alpha-linolenic acid is the eighteen-carbon plant omega-3, found in flax, chia, perilla and walnut. Eicosapentaenoic acid and docosahexaenoic acid are the twenty- and twenty-two-carbon marine and algal omega-3s. ALA is the dietary essential; EPA and DHA are the physiologically active long-chain forms, synthesised from ALA by a desaturation and elongation sequence that in humans is markedly inefficient.
The conversion problem: This is the single most consequential fact in the category. Conversion of ALA to EPA in adults is commonly estimated at 5 to 8%, and conversion to DHA at under 0.5%, with the rate lower in men than in women and further depressed by high dietary linoleic acid competing for the same desaturase enzymes. A flax-based product therefore cannot substitute for a marine or algal one where EPA or DHA is the objective, however favourably the total omega-3 figure compares.
Commercial source: ALA comes from cold-pressed or expeller-pressed seed oils. EPA and DHA come from marine fish oil, from algal fermentation, or from krill as phospholipid. Concentration from natural triglyceride to high-potency material proceeds via transesterification to ethyl esters, optionally re-esterified back to triglyceride. Powder forms are microencapsulated oils.
Evidence for Omega-3 Fatty Acid Applications
ALA does not substitute for EPA and DHA, and the conversion arithmetic should be stated on any plant omega-3 specification. Conversion of ALA to EPA in adults is commonly estimated at 5 to 8% and to DHA at under 0.5%, with men converting less efficiently than women and high dietary linoleic acid further suppressing it by competing for delta-6 desaturase. A gram of ALA from flax therefore delivers roughly 50 to 80 milligrams of EPA-equivalent and a few milligrams of DHA-equivalent. A total-omega-3 declaration that pools ALA with EPA and DHA conceals this entirely. Claim strength: High.
EPA and DHA are functionally distinct and their evidence bases should not be pooled. EPA is principally a substrate for the series-3 eicosanoids and for the E-series resolvins, placing it in inflammatory signalling; DHA is principally a structural membrane lipid, dominant in retinal photoreceptors and a major constituent of brain grey matter phospholipid. The European Union authorised vision and brain-function claims attach to DHA; the depression literature has generally favoured EPA-predominant preparations. Formulating one and claiming the other's evidence is a common and avoidable error. Claim strength: High.
The cardiovascular outcome literature is genuinely unresolved and should be represented as such. Earlier secondary-prevention trials and large cohort data supported a benefit; several subsequent large trials of mixed EPA and DHA at around 1 gram daily were null. A trial of high-dose purified icosapent ethyl, EPA alone at 4 grams daily, reported a substantial cardiovascular event reduction, while a trial of a high-dose EPA and DHA carboxylic acid preparation was stopped for futility. The divergence has been attributed variously to the EPA-only composition, the dose, and controversy over the mineral oil comparator used in the positive trial. No consensus exists. Claim strength: Emerging, and contested.
Oxidation specification is mandatory across the class and the market has a documented problem with it. Polyunsaturated fatty acids oxidise readily and the rate rises with the number of double bonds, so DHA oxidises faster than EPA, which oxidises faster than ALA. Independent surveys of commercial omega-3 products have repeatedly found a proportion exceeding voluntary oxidation limits. Require peroxide value not more than 5 milliequivalents per kilogram, anisidine value not more than 20, and TOTOX not more than 26, and verify on receipt rather than relying on a certificate of unknown age. Claim strength: High.
The contaminant panel is source-dependent and should be specified accordingly. Marine oils require heavy metals, dioxins, dioxin-like PCBs and non-dioxin-like PCBs, since these lipophilic persistent contaminants concentrate in fish oil and are subject to regulatory limits. Algal oils avoid that panel but require the production organism, the fermentation substrate and residual solvent limits. Seed oils require pesticide residues and, for cold-pressed material, attention to the oxidation state of a product that carries no added antioxidant by design. Claim strength: High.
Chemical form and declaration basis are where most labelling errors occur. A "1,000 mg fish oil" capsule typically contains around 300 milligrams of combined EPA and DHA in natural triglyceride, where a concentrate of the same capsule weight may contain 700 milligrams or more. Declaring oil weight rather than EPA and DHA content tells a formulator nothing. Triglyceride and re-esterified triglyceride forms are better absorbed than ethyl esters, particularly taken without fat; ethyl esters are the economical route to high concentration. Claim strength: High.
Sourcing omega-3 from Herbuno. We supply an omega-3 powder and a DHA 10% powder.
Three things to settle on the specification. Which fatty acids and at what content — a total-omega-3 figure that pools ALA with EPA and DHA is not a specification, because ALA converts to EPA at around 5 to 8% and to DHA at under 0.5%. The chemical form, since triglyceride absorbs better than ethyl ester and costs more. And the oxidation panel — peroxide value, anisidine value and TOTOX, verified on receipt. All lots ship with CoA and MSDS; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
Dose on EPA and DHA content individually, not on total omega-3 or oil weight. Common adult recommendations for combined EPA and DHA sit around 250 to 500 milligrams daily for general intake, with higher intakes used in the cardiovascular and triglyceride-lowering literature. The European Union authorised claims specify 250 milligrams of DHA for brain function and vision and 2 grams of EPA plus DHA for maintenance of normal blood pressure, among others. ALA recommendations are separate and expressed in grams, and cannot be converted into an EPA or DHA figure for claim purposes.
The declaration basis is the commonest source of error in this category and is worth fixing in the specification template. State EPA content, DHA content, total EPA plus DHA, and total omega-3 separately. A capsule declaring "1,000 mg omega-3" might contain 300 milligrams of EPA plus DHA in natural triglyceride fish oil, or 900 milligrams in a concentrate, or 1,000 milligrams of ALA from flax with negligible long-chain content. Those are three different products and the declaration as written does not distinguish them.
Oxidation control should shape sourcing, antioxidant system, packaging and shelf life as one decision. Require the oxidation panel per lot and verify on receipt. Specify the antioxidant system and require it declared, since mixed tocopherols, ascorbyl palmitate and rosemary extract all appear on finished labels. Nitrogen headspace, opaque packaging and cool storage are standard. Shelf life claims should rest on accelerated and real-time oxidation data for the specific format, not on a generic figure, because an encapsulated powder, a softgel and a bulk oil age differently.
For microencapsulated powders, specify the parameters a bulk-oil certificate omits: total EPA and DHA on the powder, the carrier and wall material identity for allergen and clean-label purposes, free or surface oil content as the unprotected and first-to-oxidise fraction, particle size and bulk density for blending, and oxidation markers measured on the finished powder rather than on the oil before encapsulation. Dispersion and any off-note development in the intended matrix should be tested rather than assumed.
Source selection drives the contaminant and certification work. Marine oils: heavy metals, dioxins, dioxin-like and non-dioxin-like PCBs, species identification, and a fish allergen declaration. Algal oils: production organism, fermentation substrate, residual solvents, and the vegan, kosher and halal position, which is generally simpler. Seed oils: pesticide residues, expression method, and particular attention to oxidation state in cold-pressed material carrying no added antioxidant. Krill: phospholipid content, astaxanthin content where declared, and a crustacean allergen declaration.
On the cardiovascular question, the honest technical position is worth documenting because customers will ask. Earlier secondary-prevention trials and cohort data supported benefit; several later large trials of around 1 gram daily of mixed EPA and DHA were null; a trial of purified high-dose EPA as icosapent ethyl at 4 grams daily reported a substantial event reduction; and a trial of high-dose EPA plus DHA carboxylic acid was stopped for futility. The divergence has been attributed to composition, to dose, and to controversy over the mineral oil comparator in the positive trial, and no consensus has emerged. None of this supports a consumer cardiovascular claim, and the authorised claims that do exist — blood pressure and triglyceride maintenance at stated intakes — are narrower and should be used instead.
Frequently Asked Questions — Omega-3 Fatty Acids
Can flax replace fish oil?
Not where EPA or DHA is the objective. ALA converts to EPA at roughly 5 to 8% in adults and to DHA at under 0.5%, lower in men, and further suppressed by high dietary linoleic acid competing for delta-6 desaturase. A gram of flax ALA delivers maybe 50 to 80 mg EPA-equivalent and a few mg of DHA-equivalent.
Why is a total omega-3 figure not a specification?
Because it pools three fatty acids with different functions and a hundredfold difference in conversion efficiency. A "1,000 mg omega-3" declaration could be 300 mg EPA+DHA in natural triglyceride, 900 mg in a concentrate, or 1,000 mg of ALA with negligible long-chain content. State EPA, DHA, EPA+DHA and total omega-3 separately.
How do EPA and DHA differ?
Functionally and evidentially. EPA is principally a substrate for series-3 eicosanoids and E-series resolvins, placing it in inflammatory signalling, and carries most of the mood literature. DHA is principally a structural membrane lipid, dominant in retinal photoreceptors and brain grey matter phospholipid, and carries the EU vision and brain-function claims. Their evidence does not pool.
What is the current position on cardiovascular outcomes?
Unresolved. Earlier secondary-prevention trials and cohort data supported benefit; several later large trials at around 1 g daily of mixed EPA and DHA were null; a trial of purified EPA at 4 g daily reported a substantial event reduction; and a high-dose EPA plus DHA trial was stopped for futility. Attributed variously to composition, dose and the mineral oil comparator controversy. No consensus.
What oxidation limits should I set?
Peroxide value not more than 5 meq/kg, anisidine value not more than 20, TOTOX not more than 26 — and verify on receipt rather than relying on a certificate of unknown age. Independent surveys have repeatedly found commercial omega-3 products exceeding these, so it is a live market problem.
Which contaminant panel applies?
Depends on source. Marine: heavy metals, dioxins, dioxin-like and non-dioxin-like PCBs, species ID, fish allergen. Algal: organism, fermentation substrate, residual solvents — and the vegan, kosher and halal position is simpler. Seed: pesticide residues and close attention to oxidation state in cold-pressed material with no added antioxidant. Krill: phospholipid content and a crustacean allergen declaration.